Literature DB >> 3906948

In-vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity.

A Vecchiarelli, F Bistoni, E Cenci, S Perito, A Cassone.   

Abstract

Killing of yeast cells of several species of Candida by murine phagocytic cells was assessed in vitro by a radiolabel release microassay and measurement of colony forming units. The most effective candidacidal phagocytes, i.e. polymorphonuclear and bone marrow cells, were able to kill equally well cells of any species or isolate tested, given sufficient time (4 h) and an appropriate effector: target ratio. However, C. guilliermondii, C. krusei and C. parapsilosis were killed by polymorphonuclear and bone marrow cells much more promptly (1 h) and at a significantly lower effector:target ratio than C. albicans, C. tropicalis and C. viswanathii. Moreover, there were immune effectors such as peritoneal resident macrophages and, mostly, spleen cells which were practically ineffective against C. albicans and C. tropicalis but showed significant activity against C. guilliermondii, C. krusei and C. parapsilosis, even in mice immuno-depressed with cyclophosphamide. Three isolates of C. albicans, differing in the capacity to form germ tubes, also differed in mouse virulence: the germ-tube forming isolate was the most virulent. However, they showed an identical pattern of susceptibility to killing by mouse immunoeffectors, suggesting that virulence is probably not due to the resistance of hyphal cell to phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3906948     DOI: 10.1080/00362178585380541

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  16 in total

Review 1.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

2.  Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamma interferon, tumor necrosis factor, and interleukin-1.

Authors:  E Blasi; S Farinelli; L Varesio; F Bistoni
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

Review 3.  Macrophages in resistance to candidiasis.

Authors:  A Vázquez-Torres; E Balish
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

4.  Candida tropicalis infection in normal, diabetic, and neutropenic mice.

Authors:  R A Fromtling; G K Abruzzo; D M Giltinan
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

5.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Early differential molecular response of a macrophage cell line to yeast and hyphal forms of Candida albicans.

Authors:  E Blasi; L Pitzurra; M Puliti; L Lanfrancone; F Bistoni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Interactions between human natural killer (NK) lymphocytes and yeast cells: human NK cells do not kill Candida albicans, although C. albicans blocks NK lysis of K562 cells.

Authors:  S J Zunino; D Hudig
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

8.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Quantitative analysis of opsonophagocytosis and of killing of Candida albicans by human peripheral blood leukocytes by using flow cytometry.

Authors:  E Martin; S Bhakdi
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

10.  High efficiency opsonin-independent phagocytosis of Candida parapsilosis by human neutrophils.

Authors:  Jennifer R Linden; Matthew A Maccani; Sonia S Laforce-Nesbitt; Joseph M Bliss
Journal:  Med Mycol       Date:  2010-03       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.